ELISA for Peptides

Overview

Enzyme-linked immunosorbent assay (ELISA) is one of the most widely used methods for quantifying peptides in biological matrices. It measures a peptide through a specific antibody interaction, producing a colorimetric, fluorescent, or chemiluminescent signal that correlates with peptide concentration.

ELISA is complementary to mass spec analysis — cheaper and higher-throughput for large sample sets, but lower in multiplex capability and resolution. It is used for pharmacokinetics (plasma peptide concentration), immunogenicity testing (anti-drug antibody detection), and quality control.

Formats

Direct ELISA

• Peptide immobilized on the plate (capture)
• Enzyme-labeled antibody binds directly
• Simple, fast
• Used for screening antibody binding

Indirect ELISA

• Peptide immobilized
• Primary antibody binds peptide
• Secondary enzyme-labeled antibody binds primary
• Most common format; amplifies signal
• Standard for antibody characterization

Sandwich ELISA

• Capture antibody immobilized on plate
• Sample added; peptide binds capture antibody
• Detection antibody (different epitope) added
• Enzyme-labeled tertiary (or direct detection) produces signal
• Highest specificity — requires two non-overlapping antibodies
• Standard for PK sample analysis

Competition ELISA

• Peptide or mimic immobilized
• Sample plus fixed concentration of labeled peptide or antibody
• Competition for binding; signal inversely proportional to sample peptide
• Useful when only one antibody is available
• Common for small peptides too short to accommodate two antibodies

Reagents

Antibodies

• Monoclonal antibodies preferred for quantitative work (consistent batches, well-defined epitope)
• Polyclonal antibodies useful for screening but vary batch-to-batch
• Antibody affinity ideally <1 nM for low-concentration quantification
• Check cross-reactivity against related peptides and metabolites

Enzymes

• Horseradish peroxidase (HRP) — TMB substrate produces blue → yellow (with stop solution); read at 450 nm
• Alkaline phosphatase (AP) — pNPP substrate produces yellow at 405 nm
• β-galactosidase — less common

Substrates

• TMB (3,3′,5,5′-tetramethylbenzidine) — standard HRP substrate; stopped with sulfuric acid
• Chemiluminescent substrates (ECL, Luminata) — higher sensitivity
• Fluorogenic substrates (QuantaRed, Amplex UltraRed) — high sensitivity, wider dynamic range

Plates

• High-binding polystyrene (e.g., Nunc MaxiSorp) for protein/peptide capture
• Streptavidin-coated plates for biotinylated capture
• 96-, 384-, or 1536-well formats

Sample Preparation

Plasma/serum

• Collect in appropriate anticoagulant (EDTA, heparin, citrate)
• Spin and separate quickly
• Store at -80°C; avoid repeated freeze-thaw
• May require dilution to bring into assay range
• May require protease inhibitor cocktail to prevent degradation during sampling

Tissue

• Homogenize in buffer containing protease and phosphatase inhibitors
• Centrifuge to remove debris
• Normalize to protein concentration

Standards

• Prepare in same matrix as samples (matched matrix)
• Serial dilution spanning expected sample concentrations
• Include 0-standard (matrix blank)
• Validate parallelism between standard curves in matrix and buffer

Sandwich ELISA Protocol

1. Coating: Add capture antibody (1–10 μg/mL in carbonate buffer pH 9.6), incubate overnight at 4°C
2. Wash: PBS-T, 3×
3. Block: 1–5% BSA or milk in PBS-T, 1–2 h at RT
4. Wash: PBS-T, 3×
5. Sample/standard: 100 μL per well, 1–2 h at RT or overnight at 4°C
6. Wash: PBS-T, 3–5×
7. Detection antibody: biotinylated or directly enzyme-labeled, 1–2 h at RT
8. Wash: PBS-T, 3–5×
9. Streptavidin-HRP (if biotinylated detection): 30 min at RT
10. Wash: PBS-T, 5–6×
11. Substrate: TMB, 10–30 min development
12. Stop: 2 N H₂SO₄
13. Read: 450 nm, with 570 nm reference subtraction

Standard Curve Fitting

• Four-parameter logistic (4PL) fit is standard: y = d + (a - d) / (1 + (x/c)^b)
• Where a = minimum signal, d = maximum signal, c = EC50, b = Hill slope
• Report r² and back-calculated standards (should be within ±20% of nominal)

Validation Parameters

• Accuracy — within ±20% of nominal at low, medium, high QCs (±25% at LLOQ)
• Precision — intra-assay CV <15%, inter-assay <20% (±25% at LLOQ)
• Specificity/selectivity — no interference from related peptides, matrix components
• Dilution linearity — samples diluted into standard curve recover expected concentration
• Matrix effect — spiked peptide in matrix recovers within acceptance criteria
• Stability — benchtop, freeze-thaw, long-term storage at relevant temperatures

Common Issues

High background

• Insufficient blocking → try longer block, higher BSA concentration
• Detection antibody cross-reactivity → titrate
• Dirty plates → more washes or longer wash times

Low signal

• Weak antibodies → verify by direct binding
• Insufficient capture → optimize coating concentration
• Enzyme substrate degradation → fresh reagents

Hook effect

High-dose hook: at very high analyte concentrations, signal decreases. Mitigation: run two dilutions and verify linearity.

Matrix effects

Plasma components (lipids, proteins) can inhibit or enhance binding. Mitigation: matrix-matched standards, dilute samples, use immunoaffinity extraction.

Peptide-Specific Challenges

Epitope accessibility

Short peptides may have only one epitope; sandwich format impossible. Use competition or direct formats.

Degradation products

Proteolytic metabolites may or may not be recognized, depending on antibody epitope. Characterize cross-reactivity with known metabolites.

Free vs. bound peptide

Peptides can bind to plasma proteins. Acid precipitation or organic solvent extraction may be required to release total peptide.

Immunogenicity / ADA interference

Anti-drug antibodies in clinical samples can compete with detection reagents, causing apparent drug concentration to drop. Include anti-drug antibody assay alongside PK.

Applications

Pharmacokinetics

Plasma peptide concentration profile during preclinical and clinical studies. Foundation for half-life and AUC calculations and dose conversion.

Pharmacodynamics

Measurement of biomarkers responsive to peptide (e.g., insulin, C-peptide after GLP-1 therapy).

Immunogenicity testing

Anti-drug antibody detection, titration, and neutralization assessment.

Quality control

Content assay for peptide drug products, batch release testing, stability monitoring.

Research

Quantitation of endogenous peptides, signaling intermediates, hormone levels in mechanism studies.

Complementary Techniques

• Mass spec analysis — higher specificity, multiplexing, isoform resolution
• Western blot for peptides — molecular weight confirmation
• Surface plasmon resonance — kinetic characterization of antibodies used
• Fluorescence polarization — homogeneous alternative for binding

Summary

ELISA provides sensitive, specific quantification of peptides in complex biological samples. Careful antibody selection, matrix-matched standards, and rigorous validation produce reliable data that supports every stage of peptide development from discovery through clinical trials.